Millendo Therapeutics Inc (NASDAQ:MLND) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 125,600 shares, an increase of 20.0% from the December 15th total of 104,700 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 54,700 shares, the short-interest ratio is presently 2.3 days.
MLND opened at $8.16 on Wednesday. The stock’s 50 day simple moving average is $7.04 and its 200 day simple moving average is $7.83. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.10 and a quick ratio of 5.10. Millendo Therapeutics has a 1 year low of $4.56 and a 1 year high of $17.34. The firm has a market cap of $109.92 million, a price-to-earnings ratio of -0.46 and a beta of 2.74.
Millendo Therapeutics (NASDAQ:MLND) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.04). As a group, sell-side analysts anticipate that Millendo Therapeutics will post -3.29 EPS for the current year.
A number of equities analysts recently weighed in on MLND shares. Roth Capital started coverage on Millendo Therapeutics in a report on Friday, January 10th. They set a “buy” rating and a $35.00 price objective on the stock. Zacks Investment Research cut Millendo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, ValuEngine raised Millendo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, January 3rd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Millendo Therapeutics has a consensus rating of “Buy” and a consensus target price of $23.71.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC grew its position in Millendo Therapeutics by 77.9% during the 3rd quarter. Squarepoint Ops LLC now owns 18,325 shares of the company’s stock worth $130,000 after acquiring an additional 8,025 shares during the last quarter. State Street Corp grew its position in Millendo Therapeutics by 24.6% during the 3rd quarter. State Street Corp now owns 145,243 shares of the company’s stock worth $1,033,000 after acquiring an additional 28,718 shares during the last quarter. International Biotechnology Trust PLC grew its position in Millendo Therapeutics by 187.5% during the 2nd quarter. International Biotechnology Trust PLC now owns 177,825 shares of the company’s stock worth $2,056,000 after acquiring an additional 115,965 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in Millendo Therapeutics by 270.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,593 shares of the company’s stock worth $30,000 after acquiring an additional 1,893 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Millendo Therapeutics by 62.2% during the 2nd quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock worth $3,829,000 after acquiring an additional 126,994 shares during the last quarter. Institutional investors and hedge funds own 60.08% of the company’s stock.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Read More: Cash Flow
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.